The Inflammatory Bowel Disease (IBD) Research group is in its infancy being established following the employment of an IBD nurse in August 2011. The research group has been a member of the Australian and New Zealand IBD (ANZIBD) consortium since 2011 and is working in collaboration with eleven other IBD centres across New Zealand and Australia to accurately genotype and phenotype all IBD patients under our care.
Research currently being undertaken in collaboration with the ANZIBD consortium include: genomic predictors of refractory ulcerative colitis and response to treatment, use of biologic agents in IBD pregnancies: patient and physician perceptions and biologic levels in the neonate, rectal tacrolimus in distal ulcerative colitis, patient outcomes on anti-TNF agents in Crohn’s disease in Australia. The ANZIBD consortium also collaborates with the International Genetics Consortium. The IBD research group is also interested in therapeutic optimisation through therapeutic drug monitoring of both thiopurine and biologic agents.
The group is currently collaborating with Royal Adelaide Hospital and Flinders Medical Centre in Adelaide to assess longer term outcomes of thiopurine metabolite monitoring in IBD patients. In addition, biologic level testing is in the process of being established at Liverpool Hospital in collaboration with the Department of Immunology. The research group is also involved in the FOCUS study (faecal microbiota transplantation FMT) in chronic active ulcerative colitis). The group is also interested in health literacy and patient empowerment with design of specific patient centred tools. This is being done in collaboration with other members of the ANZ consortium, Afaf Girgis at the Ingham Research Institute and Corey Siegel at Dartmouth-Hitchcock Inflammatory Bowel Disease Centre.